1. Alpert M, Diamond F, Kesselman M. Correlation between extrapyamidal and therapeutic effects of neuroleptics. Comp Psychiatry 1977;18(4):333–338.

2. Alpert M, Diamond F, Weisenfreund J, Taleporos E, Friedhoff AJ. The neuroleptic hypothesis: study of covariation of extrapyramidal and therapeutic drug effects. Br J Psychiatry 1978;133:169–175.

3. Andreasen N. Modified scale for the assessment of negative symptoms (SANS). Iowa City: University of Iowa, 1984.

4. Bowers MB, Swigar ME, Jatlow PI, Giocoechea N. Plasma catecholamine metabolites and early response to haloperidol. J Clin Psychiatry 1984;45:248–251.

5. Bowers MB, Swigar ME, Jatlow PI, Hoffman FJ, Goicoecha N. Early neuroleptic response: clinical profiles and plasma catecholamine metabolites. J Clin Psychopharmacol 1987;7:83–86.

6. Chang WH, Chen TY, Lee CF, Hung JC, Hu WH, Yeh EK. Plasma homovanillic acid levels and subtyping of schizophrenia. Psychiatry Res 1988;23:239–244.

7. Davidson M, Davis KL. A comparison of plasma homovanillic acid concentrations in schizophrenic patients and normal controls. Arch Gen Psychiatry 1988;45(6):561–563.

8. Davidson M, Kahn RS, Warne P, et al. Changes in plasma homovanillic acid concentrations in schizophrenic patients following neuroleptic discontinuation. Arch Gen Psychiatry 1991;48:73–76.

9. Davidson M, Losonczy MF, Mohs RC, et al. Effects of debrisoquin and haloperidol on plasma homovanillic acid concentration in schizophrenic patients. Neuropsychopharmacology 1987;1:17–23.

10. Davila R, Gonzales-Torres M, Zumarraga M, Andia I, Guimon J, Friedhoff AJ. The ratio of plasma prolactin to homovanillic acid: a good predictor of clinical response in schizophrenia. [Submitted.]

11. Davila R, Manero E, Zumarraga M. Plasma homovanillic acid as a predictor of response to neuroleptics. Arch Gen Psychiatry 1988;45:564–567.

12. Davis KL, Davidson M, Mohs RC, et al. Plasma homovanillic acid concentration and the severity of schizophrenic illness. Science 1985;227:1601–1692.

13. Davis KL, Kahn RS, Ko G, et al. Dopamine in schizophrenia. Am J Psychiatry 1991;148:1474–1486.

14. Friedhoff AJ. Catecholamines and behavior. In: Ramachandran VS, ed. Encyclopedia of human biology. San Diego: Academic Press; 1991:217–224.

15. Green AI, Alam MY, Boshes RA, et al. Haloperidol response and plasma catecholamines and their metabolites. Schizophr Res 1993; 10:33–37.

16. Grodsky GM. Chemistry and functions of the hormones: in thyroid, pancreas, adrenal and gastrointestinal tract. In: Harper HA, Rodwell VW, Mayers PA, eds. Review of physiological chemistry. California: Lang Medical; 1979:511–555.

17. Landsberg L, Young JB. Physiology and pharmacology of the autonomic nervous system. In: Wilson JD, Braunwald E, Isselbacher KF, et al. eds. Principles of internal medicine. New York: McGraw-Hill; 1991:380–389.

18. Matthysse S. Antipsychotic drug actions: a clue to neuropathology of schizophrenia? Fed Proc 1973;32:200–205.

19. Mazure CM, Nelson JC, Jatlow PI, Bowers MB. Plasma free homovanillic acid (HVA) as a predictor of clinical response in acute psychosis. Soc Biol Psychiatry 1991;30:475–482.

20. Meltzer H. Duration of a clozapine trial in neuroleptic-resistant schizophrenia. Arch Gen Psychiatry 1989;46:672.

21. Pickar D, Labarca R, Linnoila M, et al. Neuroleptic-induced decrease in plasma homovanillic acid and antipsychotic activity in schizophrenic patients. Science 1984;225:954–957.

22. Pickar D, Labarca R, Doran AR. Longitudinal measurement of plasma homovanillic acid levels in schizophrenic patients. Arch Gen Psychiatry 1986;43:669–676.

23. Steinberg JL, Garver DL, Moeller FG, Raese JD, Orsulak PL. Serum homovanillic acid levels in schizophrenic patients and normal control subjects. Psychiatry Res 1993;48:93–106.

24. Van Kammen DP. The biochemical basis of relapse and drug response in schizophrenia: review and hypothesis. Psychol Med 1991;21:881–895.

25. Van Putten T, Marder SR, Aravagiri M, Chabert N, Mintz J. Plasma homovanillic acid as a predictor of response to fluphenazine treatment. Psychopharm Bull 1989;1:89–91.